Jessica S. Donington, MD of NYU Langone Health discusses the changes in stage 3A NSCLC using immunotherapy in resectable patients.…
Browsing: Acute Lymphoblastic Leukemia
Joshua Bauml, MD of the University of Pennsylvania discusses immunotherapy in lung cancer and the 15-20 percent response rate of…
Jessica S. Donington, MD of NYU Langone Health discusses the surgical dilemmas in the management of locally advanced NSCLC. Dr.…
Joshua Bauml, MD of the University of Pennsylvania discusses the fact that HER2 is over expressed in 60 percent of…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how T790M testing is practically standard for EGFR activating…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses the Pacific Trial overview of Durvalumab in locally advanced…
Laura Jean Bierut, MD of Washington University of Medicine discusses the three levels of smoking cessation. These levels are (1)…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses his concerns over the PACIFIC Trial data such as…
Laura Jean Bierut, MD of Washington University of Medicine discusses the benefits of E-Cigarettes over combustible cigarettes. First and foremost,…
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about the FLAURA Trial Results and the 8-9 Month…
Laura Jean Bierut, MD of Washington University of Medicine talks about E-Cigarettes and how they may be the greatest public…
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how in EGFR Activating Mutations, Osimertinib is now the…
Laura Jean Bierut, MD of Washington University of Medicine discusses the two main nicotine responders genetic variations and metabolic enzymes.…
Corey J. Langer, MD, FACP of the University of Pennsylvania talks about 2018 NSCLC trends in prognosticate refinement and the…
Laura Jean Bierut, MD of Washington University of Medicine discusses 400,000 vs 60,000 fatalities per year lung cancer vs opioid…
Tracey L. Evans, MD of the University of Pennsylvania describes what determines using osimertinib in first line treatment. Dr. Evans…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses osimertinib & small cell transformation. There is a very…
Tracey L. Evans, MD of the University of Pennsylvania discusses T790 mutation testing on initial diagnosis. Testing T790M before the…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses management of EGFR-resistant disease and T790M mutations. Management of…
Laura Jean Bierut, MD of Washington University of Medicine talks about when to focus on smoking cessation. There are two…
Tracey L. Evans, MD of the University of Pennsylvania discusses incomplete resections in NSCLC. What to do with incomplete resection,…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses the FLAURA study and improvement in PFS over standard…
Tracey L. Evans, MD of the University of Pennsylvania discusses the impact of immunotherapy in thoracic oncology. Immunotherapy data is…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses T790M mutation and the role of osimertinib in the…
Tracey L. Evans, MD of the University of Pennsylvania describes why Osimertinib is such an important breakthrough in EGFR mutated…
Lyudmila Bazhenova, MD of the University of California, San Diego discusses Metastatic EGFR mutation + Osimertinib in NSCLC first line,…
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed…
Patient reported symptom burden and peripheral blood counts among PV patients.
Elderly cancer patients tend to have more complex conditions, and therefore require a strong support system to assist their needs…
With age being the biggest risk factor for cancer, and an ageing population in the UK, the NHS is having…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented cutting-edge updates in hematology. Discover…
In this exciting interview, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK,…
The primary thrombocythemia (PT)-1 trial (NCT00175838) comprises a series of three studies, which have been running since 1997 and include…
There was a long period of time without new acute myeloid leukemia (AML) treatments, but now there are a number…
This is an incredibly exciting time for multiple myeloma (MM) research. In this video, some of the most interesting topics…
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune…
The University of Birmingham has partnered with Leuka, NHS Blood and Transplant, and Anthony Nolan to deliver the UKs first…
Understanding the biology of human disease is of the utmost importance to advancing treatment. We are now making excellent headway…
Relapse remains the main obstacle for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic stem cell…
For high-risk acute myeloid leukemia (AML), azacitidine monotherapy is typically utilized. However, there is a low overall response rate and…
The outcome for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation remains poor.…
Dr. Susanne Osanto discusses the use of chemotherapy plus androgen deprivation therapy (ADT) for newly diagnosed men with advanced stage…
The Multiple Myeloma Research Foundation (MMRF) has been very active throughout 2017. Here, Daniel Auclair, PhD, of the MMRF, Norwalk,…
Clinical trials and research, regardless of their degree of success, provide useful lessons that can be applied to a range…
The ongoing Phase III ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in patients…
Venetoclax is a BCL-2 inhibitor used in the treatment of chronic lymphocytic lymphoma (CLL), which works through increasing the apoptosis…
Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of…
There were many advancements presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,…
The scientific advances reported at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, were…
The American Society of Hematology (ASH) Annual Meeting and Exposition has become the go-to place for hematology updates for scientists,…